Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity
US6451853B1 · kind B1 · utility
7Cited by
5References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 1999 |
| Grant date | Sep 17, 2002 |
| Priority date | — |
| Expiry date | Feb 24, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of using peptide-like compounds, e.g., aminocarboxylic acid amide derivatives, to bias the immune system toward producing, enhancing, or maintaining a polarized Th1 response, and to methods for treating diseases that improve by creating a Th1 response. The invention also relates to a method of treating diseases associated with elevated soluble TNF alpha levels by administering beta-alethine together with NAC to reduce soluble TNF alpha, and to a pharmaceutical composition comprising same. The present compounds can be used to modulate cytokines including IFN-gamma and IL-10.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.